About This Deal
Gilead Sciences acquired Kite Pharma, Inc. for ~$11.9 billion, a transaction announced in August 2017.
Acquired the CAR T-cell therapy pioneer for $180.00 per share in cash, immediately positioning Gilead as a leader in cell therapy and adding lead CAR T candidate axicabtagene ciloleucel (Yescarta).
Acquired the CAR T-cell therapy pioneer for $180.00 per share in cash, immediately positioning Gilead as a leader in cell therapy and adding lead CAR T candidate axicabtagene ciloleucel (Yescarta).
Deal Terms
Acquirer
Gilead Sciences
Target
Kite Pharma, Inc.
Value
~$11.9 billion
Date
August 2017
Type
Full acquisition
Status
Completed
Transaction Details
Announced
August 28, 2017
In Their Words
Gilead Sciences to acquire Kite Pharma for $11.9 billion, immediately positioning Gilead as a leader in cell therapy.
Advisors
Advisory firms were not disclosed for this transaction.
Related Deals & Entities
Sources:
Press release ↗
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.